Omeros Corporation (LON:0KBU)

Market Cap	583.56M +39.8%
Revenue (ttm)	n/a
Net Income	-90.14M
EPS	-1.50
Shares Out	n/a
PE Ratio	n/a
Forward PE	8.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	501
Average Volume	4,453
Open	11.15
Previous Close	11.42
Day's Range	11.03 - 11.31
52-Week Range	2.95 - 18.98
Beta	2.38
RSI	44.36
Earnings Date	Mar 12, 2026

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-bind...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1994
• Employees: 202
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0KBU

Financial Performance

Financial numbers in USD